Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results ...
24/7 Wall St. on MSN
Buy, hold, or sell: Tech compression dragged Abbott Labs under $91, but 1 massive diabetes catalyst makes it a screaming buy
Quick ReadABT fell 27% year to date, but FreeStyle Libre's 14% CGM growth and a forward P/E of 16 make it a buy.Despite ...
Data from Abbott’s REFLECT study show for the first time that the use of its continuous glucose monitoring technology, Freestyle Libre, can help lessen the severity of cardiovascular complications in ...
MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus * sensor, is now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results